In full disclosure, the following press release and photo were submitted to SOURCE media via its business news service.
NATICK – Allurion, a company dedicated to eliminating obesity, has received approval to launch its revolutionary gastric balloon technology in Brazil.
The Allurion Balloon – known in Brazil as the Elipse Balloon – is the first and only intragastric weight loss balloon that is systematically placed and removed without surgery, endoscopy or anesthesia1. With its launch in Brazil, the Allurion ball is now available in 60 countries.
The prevalence of obesity in Brazil increased from 11.8% in 2006 to 20.3% in 2019.
By 2030, nearly 30% of Brazil’s adult population will be obese.
Accordingly, Allurion estimates a total addressable market of approximately 1.3 million consumers in Brazil who would be eligible and consider choosing the Allurion program.
Dr. Shantanu Gaur, co-founder and CEO of Allurion, says the need to tackle obesity in Brazil is more urgent than ever.
“Obesity represents one of the most important health problems in Brazil today (Friday, October 28). We welcome ANVISA’s approval and look forward to working with healthcare professionals and other weight loss experts to end obesity in the country.
Benoit Chardon, chief commercial officer of Allurion, said the approval was just the company’s latest push into markets where obesity was a serious health concern.
“We are confident in our future success in Brazil, as we have three major advantages: the revolutionary and procedure-free nature of our device, the comprehensive nature of our program which includes an AI-powered remote patient monitoring system and a behavior change program that complements the device, and the experience we have accumulated after treating more than 100,000 patients around the world,” he says.
The Allurion program is available in 5 clinics in Brazil, with 7 more opening soon. As with other markets, Chardon says Allurion will initially be selective in partnering with clinics to offer the program. “We want to ensure the best-in-class experience for all of our patients: only the most experienced teams and clinics will be trained to deliver this sophisticated program,” he says.
To date, the company has demonstrated clear product-market fit in over 50 countries and has grown revenue by 100% year over year over the past 6 years. With launches this year in Australia, Canada, Mexico, India and now Brazil, the company has nearly doubled its footprint in the last 12 months alone.
Dr. Eduardo Grecco, gastric surgeon and endoscopist at Instituto Endovitta in São Paulo, Brazil, welcomed an additional tool to help fight obesity.
“According to Secretária de Vigilância em Saúde, our local health monitoring agency, approximately 20% of the adult population currently lives with obesity and a further 36% are overweight. This represents almost 95 million people,” says- he.
“We have seen an 80% increase in obesity over the past 10 years, particularly among 25 to 45 year olds. This has a ripple effect on other conditions where obesity is a contributing factor. major risk.”
Dr. Manoel Galvao Neto, head of bariatric endoscopy at Mohak Bariatric and Robotics and scientific director at Instituto Endovitta, agrees. “It’s really important that we act now to help these people lose weight. Having tools like the Allurion program at our disposal is going to be a game-changer.”
About the Allurion balloon (marketed as the Elipse balloon in Brazil)
- The Allurion Swallowing Gastric Balloon is the world’s first and only no-procedure weight loss device. It does not require surgery, endoscopy or anesthesia for routine placement or removal1. In Brazil, it is indicated for adults with a body mass index (BMI) of 30 to 40
- It is part of the Allurion program, which helps patients make positive lifestyle changes that lead to long-term weight loss. The holistic program includes support from a physician and nutritionist, as well as a suite of digital tools designed to help maximize success.
- The Allurion program is for people who are unable to achieve their weight loss goals through diet alone and those who are unwilling or unable to undergo invasive surgery or endoscopy. It may also be suitable for people who have to manage weight-related comorbidities, such as diabetes, infertility or cardiovascular disease.
* Calculations of total market opportunities are based on current health statistics, revenue levels and market penetration of the company
** Estivaleti, JM, Guzman-Habinger, J., Lobos, J. et al. Temporal trends and projection of the obesity epidemic in Brazilian adults between 2006 and 2030. Scientific representative 12, 12699 (2022). https://doi.org/10.1038/s41598-022-16934-5
1 In rare cases, the Allurion Balloon may require endoscopic or surgical intervention to remove
Allurion is dedicated to ending obesity. The Allurion Program is a 360-degree weight loss experience with the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-free.1 gastric balloon for weight loss, Allurion Virtual Care Suite including Allurion mobile app for consumers, Allurion Insights for clinicians with Iris AI platform and Allurion Connected Scale and Health Tracker devices. The Allurion VCS is now available to providers separately from the Allurion program to help personalize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company’s head office is in Natick.